Otsuka Plans ¥1 Trillion IPO To Expand Beyond Abilify And Soyjoy
This article was originally published in PharmAsia News
Executive Summary
Aiming at expanding beyond its blockbuster schizophrenia drug and widely popular personal care products, Japan's fifth-largest drug maker Otsuka Pharmaceutical is reportedly preparing an initial public offering in Tokyo estimated to be valued at over ¥1 trillion ($12 billion) based on calculations of the stock option exercise price, making Otsuka one of the largest Japanese drug makers to go public in a decade
You may also be interested in...
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Building on deals in AMD and dry eye, the U.S. eye care startup will conduct trials on a novel glaucoma treatment, with an option to co-promote.